J01GB01 ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
299Cystic fibrosis2

299. Cystic fibrosis


Clinical trials : 1,695 Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2012-004437-16-NL
(EUCTR)
15/05/201319/03/2013Pharmacokinetic evaluation and local tolerability of dry powder tobramycin by a novel device in patients with non cystic fibrosis bronchiectasisPharmacokinetic evaluation and tolerability of dry powder tobramycin by a novel device in patients with non cystic fibrosis bronchiectasis - Tobra-02 BronchiectasisLung infections;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]Product Name: Dry powder tobramycin
Product Code: J01GB01
INN or Proposed INN: Tobramycin dry powder
Other descriptive name: TOBRAMYCIN
University Medical Center GroningenNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Netherlands
2EUCTR2016-005014-21-NL
(EUCTR)
31/10/2020Pharmacokinetic evaluation and tolerability of dry powder tobramycin viathe Cyclops® in children with cystic fibrosisPharmacokinetic evaluation and tolerability of dry powder tobramycin via the Cyclops® in children with cystic fibrosis - DPI-tobra-child Cystic FibrosisLung infections;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]Product Name: Dry powder tobramycin
Product Code: J01GB01
INN or Proposed INN: TOBRAMYCIN
Other descriptive name: TOBRAMYCIN
Product Name: Nebulization tobramycin
INN or Proposed INN: TOBRAMYCIN
Other descriptive name: TOBRAMYCIN
University Medical Center GroningenNULLNAFemale: yes
Male: yes
10Phase 2Netherlands